Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $3,263,656.50 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 5,850 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total value of $3,263,656.50. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Thermo Fisher Scientific Price Performance

TMO stock traded down $2.45 on Monday, reaching $555.47. The company had a trading volume of 815,100 shares, compared to its average volume of 1,463,423. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The company’s fifty day moving average is $599.39 and its 200 day moving average is $583.76. The company has a market cap of $212.19 billion, a P/E ratio of 34.98, a PEG ratio of 3.61 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1 year low of $437.26 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.69 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in TMO. Signature Resources Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. New Millennium Group LLC acquired a new stake in Thermo Fisher Scientific during the second quarter worth about $29,000. Stephens Consulting LLC lifted its stake in shares of Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 29 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $32,000. Finally, Bank & Trust Co purchased a new position in Thermo Fisher Scientific in the second quarter valued at approximately $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. Sanford C. Bernstein lowered their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research report on Thursday, October 24th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Finally, TD Cowen boosted their target price on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.